Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have earned a consensus rating of “Hold” from the nineteen analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $75.63.
A number of brokerages have recently issued reports on CRSP. Needham & Company LLC dropped their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Finally, Barclays lowered their target price on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th.
View Our Latest Report on CRISPR Therapeutics
Hedge Funds Weigh In On CRISPR Therapeutics
CRISPR Therapeutics Trading Down 2.6 %
CRSP stock opened at $48.18 on Thursday. The stock has a market capitalization of $4.09 billion, a PE ratio of -17.71 and a beta of 1.68. The stock’s 50 day simple moving average is $50.45 and its 200 day simple moving average is $57.00. CRISPR Therapeutics has a 12-month low of $37.55 and a 12-month high of $91.10.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the prior year, the firm posted ($0.98) earnings per share. CRISPR Therapeutics’s quarterly revenue was down 99.3% on a year-over-year basis. On average, research analysts predict that CRISPR Therapeutics will post -5.6 earnings per share for the current year.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
- Five stocks we like better than CRISPR Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 9/16 – 9/20
- Options Trading – Understanding Strike Price
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.